Clinical Trials on TP53 R249S

Total 38 results

Chinese PLA General Hospital
Zhejiang University

Recruiting

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

Lymphoma | Solid Tumor, Adult | EphA2 Overexpression | TP53 R273H | TP53 R175H | TP53 R248Q | TP53 R249S

China
Zhejiang University

Recruiting

Venetoclax and Decitabin Based Conditioning Regimen Followed With Post-HSCT Decitabin Maintenance Therapy in TP53 Mutant AML/MDS Patients

Hematopoietic Stem Cell Transplantation | TP53

China
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen... and other collaborators

Recruiting

Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT

Allogeneic Hematopoietic Stem Cell Transplantation | Conditioning | TP53 | Myeloid Tumors

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

NSCLC | EGFR Activating Mutation | Anlotinib | TP53 | Aumolertinib
Moy-Fincher-Chipps Facial Plastics and Dermatology

Unknown

To Evaluate and Compare p53 Epidermal Expression in Healthy Volunteers 3 Months After Treatment With a 2,940-nm Fractional Ablative Erbium Laser and Topical DNA Repair Enzymes

p53 Expression
Shanghai Changzheng Hospital

Unknown

Arsenic Trioxide for Structural p53 Mutations

Refractory Cancer | Arsenic Trioxide | p53 Mutations | Intractable Cancer

China
Ruijin Hospital

Recruiting

Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS (PANDA-T0)

P53 Mutation | Myeloid Malignancy | MDS | Aml

China
Novartis Pharmaceuticals

Completed

A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors (CCGM097X2101)

Solid Tumor With p53 Wild Type Status

France, Germany, Singapore, Switzerland, United States
Haukeland University Hospital

Terminated

The p53 Colorectal Cancer Trial

Colorectal Cancer Metastatic | Colorectal Cancer Stage IV | TP53 Gene Mutation

Norway
National Cancer Institute (NCI)

Recruiting

Clinical and Genetic Studies of Li-Fraumeni Syndrome

Neoplasms | Li-Fraumeni Syndrome | Tp53 Mutations

United States
Cancer Institute and Hospital, Chinese Academy...

Unknown

Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.

Diffuse Large B-Cell Lymphoma | Sintilimab | TP53 Mutation
The First Affiliated Hospital of Xiamen University
Shanxi Province Cancer Hospital; Sun Yat-sen University; Jiangsu Provincial People... and other collaborators

Recruiting

AZA Combined With RCHOP in P53-mutated DLBCL.

DLBCL - Diffuse Large B Cell Lymphoma | TP53

China
Federal University of São Paulo

Completed

Oral Isotretinoin for Photoaging: Results of a Randomized Controlled Phase II Trial

Photoaging | Epidermal p53 Expression

Brazil
Ruijin Hospital

Not yet recruiting

CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors

B-NHL, Extranodal, TP53 Alterations, Bulky Mass
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Endometrial Carcinoma | Recurrent or Metastatic | TP53 Mutation

China
Jonsson Comprehensive Cancer Center
AstraZeneca

Active, not recruiting

18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma

Glioblastoma | Recurrent Glioblastoma | EGFR Gene Mutation | Supratentorial Glioblastoma | EGFR Gene Amplification | TP53 wt Allele

United States
Scripps Health
J. Craig Venter Institute

Completed

Biomarker Monitoring in TP53 Mutation Carriers

Li-Fraumeni Syndrome | Hereditary Cancer Syndromes | TP53 Gene Germline Mutation Carrier

United States
Dr Cipto Mangunkusumo General Hospital

Completed

Patogenic Mutation in 5 Genes

Colorectal Cancer | APC Gene Mutation | TP53 Gene Mutation | PIK3CA Gene Mutation | KRAS Mutation-Related Tumors | MLH1 Gene Mutation

Indonesia
Dana-Farber Cancer Institute
National Cancer Institute (NCI); Baylor College of Medicine; City of Hope Medical...

Recruiting

Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress (LiFT_UP)

TP53 Gene Mutation | Li-Fraumeni Syndrome | Hereditary Cancer Syndrome | Mosaicism | Clonal Hematopoiesis

United States
Li Junmin

Unknown

Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations

Acute Myeloid Leukemia | P53 Mutation

China
First Affiliated Hospital of Jinan University
Ruijin Hospital

Recruiting

Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations

Acute Myeloid Leukemia | Myelodysplastic Syndromes | P53 Mutation | Myeloid Malignancy | Temperature-Sensitive p53 Mutation | Sodium Stibogluconate

China
Instituto do Cancer do Estado de São Paulo

Completed

Phenotype and Prognosis of Patients With Breast Cancer and Pathogenic Variants of TP53 (BREAST-TP53)

Breast Cancer | Li-Fraumeni Syndrome | TP53 R337H | Prognosis Breast Cancer

Brazil
Cumhuriyet University

Completed

Is There Any Relation Between Serum Anti-p53 Antibody and TLG, MTV and SUV as PET Parameters in Lung Cancer Patients?

Lung Neoplasms | Gene, p53

Turkey
Dana-Farber Cancer Institute
Eli Lilly and Company

Not yet recruiting

ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab

Endometrial Cancer | Recurrent Endometrial Cancer | TP53

United States
University Health Network, Toronto

Withdrawn

Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer

Fallopian Tube Cancer | Primary Peritoneal Cancer | Ovarian Endometrioid Tumor | TP53 Mutation

Canada
National Cancer Institute (NCI)

Completed

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

Anti-p53 TCR-Gene

United States
AstraZeneca

Completed

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation

United States, Canada, Netherlands
Li Junmin

Withdrawn

Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)

Myelodysplastic Syndromes | P53 Mutation

China
Yang Li
Ruijin Hospital

Recruiting

Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer

Pediatric Cancer | Li-Fraumeni Syndrome | p53 Mutations

China
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Role of p53 Gene in Metabolism Regulation in Patients With Li-Fraumeni Syndrome

Mitochondrial Disorders | Li-Fraumeni Syndrome | Carriers of p53 Mutation

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
University Health Network, Toronto

Recruiting

A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer (CAN-STAMP)

Endometrial Carcinoma | P53 Mutation | Serous Carcinoma

Canada
St. Jude Children's Research Hospital
Novartis Pharmaceuticals

Active, not recruiting

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Glioma | Neoplasms | Glioblastoma | Neoplasms, Neuroepithelial | Central Nervous System Neoplasms | Brain Cancer | Brain Tumor | Ependymoma | Medulloblastoma | Anaplastic Astrocytoma | Anaplastic Ganglioglioma | Anaplastic Ependymoma | Anaplastic Oligodendroglioma | Pineoblastoma | Recurrent Medulloblastoma | CNS Tumor | Pediatric... and other conditions

United States
Aprea Therapeutics

Completed

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

United States, France, Spain, Netherlands, United Kingdom, Belgium, Germany, Sweden
Masonic Cancer Center, University of Minnesota

Recruiting

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | AML | Acute Leukemia | Neurofibromatosis 1 | Hematologic Malignancy | Myelodysplasia | Minimal Residual Disease | Chromosome Abnormality | Monosomy 7 | Remission | Somatic Mutation | Cytogenetic Abnormality | TP53 | Fetal Hemoglobin | Intrachromosomal Amplification of Chromosome... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

Melanoma | Soft Tissue Sarcoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Head and Neck Squamous Cell Carcinoma | Bladder Carcinoma | Colon Carcinoma | Pancreatic Carcinoma | Rectal Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma and other conditions

United States
Ascentage Pharma Group Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Melanoma | P53 Mutation | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Malignant Peripheral Nerve Sheath Tumors | MPNST | Unresectable or Metastatic Melanoma or Advanced Solid Tumors | MDM2 Gene Mutation

United States, Australia
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Terminated

Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies

Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Minimal Residual Disease | Therapy-Related Acute Myeloid Leukemia | Therapy-Related Myelodysplastic... and other conditions

United States

Clinical Trials on TP53 R249S

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations